<DOC>
	<DOCNO>NCT02385266</DOCNO>
	<brief_summary>The purpose study evaluate efficacy D-Cycloserine versus placebo treatment reduce pain urological chronic pelvic pain syndrome ( UCPPS ) .</brief_summary>
	<brief_title>Treating Urological Chronic Pelvic Pain Syndrome ( UCPPS ) Pain</brief_title>
	<detailed_description>This double blind , randomize control trial ( RCT ) 21 week period aim evaluate treatment efficacy placebo D-cycloserine ( DCS ) men suffer UCPPS . The brain functional anatomical property associate treatment response also examine . This study emphasize comparing , clinically brain imaging , analgesic response placebo placebo responder non-responders addition novel treatment ( DCS ) target brain 's pain mechanism UCPPS . Subjects randomize 2 arm , 1:1 ratio , DCS medication group ( n=20 ) placebo medication group ( n=20 ) . Questionnaire outcomes brain scan occur prior initiating treatment end treatment period . The actual visit require minimize , 9 visit spread 21 week , pain , quality life pill ingestion timing collect use secure study website accessible electronically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>Males great 18 year age , racial/ethnic restriction ; Meets diagnostic criterion Interstitial Cystitis Painful Bladder Syndrome ( IC/PBS ) and/or Chronic Prostatitis Chronic Pelvic Pain Syndrome ( CP/CPPS ) ; Reports symptom discomfort pain pelvic abdominal region least 3 mo period within last 6 mo ; Must Visual Analog Scale ( VAS ) pain score &gt; 40 mm ( 100 mm maximum ) baseline visit ( UCPPS pain moderate severe ) ; Must generally stable health ; Must willing abstain drinking alcohol course study ; Must able read speak English willing read understand instruction well questionnaire ; Must sign inform consent document complete explanation study document understand purpose study , procedure undertake , possible benefit , potential risk , willing participate . Urological pain associate systemic sign symptom , e.g. , fever , chill ; Evidence facultative Gram negative enterococcus value â‰¥ 100,000 CFU/ml midstream urine ( VB2 ) ; Has second chronic pain condition ( e.g. , chronic low back pain , temporomandibular joint syndrome , etc . ) would prevent clear interpretation study result ; History tuberculous cystitis , bladder cancer , carcinoma situ , prostate cancer , urethral cancer ; History significant pelvic comorbidities , include inflammatory bowel disease ( Crohn 's disease ulcerative colitis ) , undergone pelvic radiation , systemic chemotherapy , intravesical chemotherapy , treat intravesical Bacillus CalmetteGuerin ( BCG ) unilateral orchialgia without pelvic symptom , active urethral stricture , ureteral calculus , urethral diverticulum , neurological disease disorder affect bladder ; Significant medical conditions/diseases , significant renal disease history renal insufficiency , unstable diabetes mellitus , congestive heart failure , coronary peripheral vascular disease , chronic obstructive lung disease , malignancy ; Neurologic disorder , include history seizure ; Major psychiatric disorder past 6 month ; Moderate severe depression , determine Hospital Anxiety Depression Scale , active suicidal ideation ; History , current , substance abuse/dependence include alcohol ; Known sensitivity Dcycloserine ; Currently take follow medication : ethionamide , dilantin , isoniazid ( INH ) , pyridoxine ( vitamin B6 ) Use therapeutic dos antidepressant medication ( i.e. , tricyclic depressant , Selective Serotonin Reuptake Inhibitor ( SSRIs ) , SerotoninNorepinephrine Reuptake Inhibitor ( SNRIs ) ; low dos use sleep may allow ) , medication alter pain transmission ; Current use low dose aspirin ; Indication subject unlikely compliant due unmanaged medical psychological condition ( ) , include neurological , psychological , speech/language problem interfere prevent understanding consent , ability comply protocol ability complete study ; Any change medication urological pain last 30 day ; High dose opioid prophylaxis , define &gt; 50mg morphine equivalent/day ; Any medical condition investigator 's judgment may prevent individual completing study put individual undue risk ; In judgment investigator , unable unwilling follow protocol instruction ; Evidence poor treatment compliance , judgment investigator ; Intraaxial implant ( e.g . spinal cord stimulators pump ) ; All exclusion criterion Magnetic Resonance ( MR ) safety : metallic implant , brain skull abnormality , tattoo large body part , claustrophobia .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Interstitial cystitis Painful Bladder Syndrome</keyword>
	<keyword>Urological Chronic Pelvic Pain Syndrome</keyword>
</DOC>